MeSH D003248 - constipation
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012817:Digestive signs and symptoms
0 Companies
0 Drugs
Success rate
D003248:Â
Constipation
D000079689:Opioid-induced constipation
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Salix Pharmaceuticals | Methylnaltrexone | Relistor | 2024-04-08 | 2008-04-24 |  |  |
| Plecanatide | Trulance | 2022-03-28 | 2017-01-19 |  |  | |
| Ascorbic acid, Polyethylene glycol 3350 | Moviprep | 2024-09-01 | 2006-08-02 |  |  | |
| Ascorbic acid, Polyethylene glycol 3350 | Plenvu | 2032-03-09 | 2018-05-04 |  |  | |
| Teva | Lactulose | Evalose |  | 1993-05-28 |  |  |
| Lactulose | Heptalac |  | 1993-05-28 |  |  | |
| Lubiprostone | Lubiprostone |  | 2022-01-18 |  |  | |
| Mylan | Linaclotide | Linaclotide |  | 2021-02-09 |  |  |
| AbbVie | Linaclotide | Constella |  | 2012-11-26 |  |  |
| Linaclotide | Linzess | 2024-01-28 | 2012-08-30 | $873 M | Q3/24-Q2/25 | |
| Sanofi | Lactulose | Cephulac |  | 1982-01-01 |  |  |
| Lactulose | Chronulac |  | 1982-01-01 |  |  | |
| Bausch Health Companies | Methylnaltrexone | Relistor |  | 2008-07-01 |  |  |
| Xttrium Laboratories | Lactulose | Lactulose |  | 2002-02-21 |  |  |
| Takeda | Prucalopride | Motegrity |  | 2018-12-14 |  |  |
| Prucalopride | Resolor |  | 2009-10-14 |  |  | |
| Dr Reddys Laboratories | Lubiprostone | Lubiprostone |  | 2022-02-08 |  |  |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
48%11/23
Phase 2
74%23/31
Phase 3
92%46/50
Approved: 23Overall Success rate: 33%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use